Antibiofilm effects of mucolytic drugs

Authors

  • А.Е. Abaturov State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine http://orcid.org/0000-0001-6291-5386
  • O.O. Rusakova State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2224-0551.15.6.2020.215536

Keywords:

bacterial biofilms, dispersion, N-acetylcysteine

Abstract

Mucolytic drugs have the ability to disrupt the structure of the matrix and destroy the formed bacterial biofilms. The most studied is N-acetylcysteine. Ciro Pérez-Giraldo et al. first demonstrated the antibiofilm activity of N-acetylcysteine in 1997, which showed that it has an inhibitory effect on bacterial growth and induces the dispersion of biofilms formed by bacteria Staphylococcus epidermidis. N-acetylcysteine has been established to have a pronounced activity against biofilms formed by various gram-positive and gram-negative bacteria, including antibiotic-resistant bacterial strains of methicillin-resistant Staphylococcus aureus and quinolone-resistant Pseudomonas aeruginosa. N-acetylcysteine promotes penetration of penicillins, polymyxins, fluoroquinolones into the deepest layers of the biofilm, overcoming the antibiotic resistance of causative bacterial agents. N-acetylcysteine can be used as an antibiotic drug for chronic bacterial-associated diseases, in particular, episodes of respiratory infections in patients with cystic fibrosis, chronic bronchitis, and chronic obstructive pulmonary disease. N-acetylcysteine is believed to be a drug with an excellent safety and efficacy profile in the treatment of diseases that are accompanied by the formation of bacterial biofilms. N-acetylcysteine and nanotechnological drugs, in which its molecules are combined with gallium or silver particles, are medicines that can become the drugs of choice that disperse biofilms and enhance the effectiveness of antibiotic therapy, especially for diseases caused by antibiotic-resistant strains of microorganisms.

Downloads

Download data is not yet available.

References

Abaturov AE, Volosovets AP, Borisova TP. Drug management of oxidation-reduction state of the body in respiratory tract diseases (part 3). Zdorov`e rebenka. 2018;5(13):197-202. doi:10.22141/2224-0551.13.5.2018.141574. (in Russian).

Ivashev MN, Sergienko AV. Clinical pharmacology of acetylcysteine. Uspekhi sovremennogo estestvoznaniia. 2013;5:116-117. (in Russian).

Adegoke AA, Stenström TA, Okoh AI. Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy. Front Microbiol. 2017 Nov 30;8:2276. doi:10.3389/fmicb.2017.02276.

Adil M, Amin SS, Mohtashim M. N-acetylcysteine in dermatology. Indian J Dermatol Venereol Leprol. 2018 Nov-Dec;84(6):652-659. doi:10.4103/ijdvl.IJDVL_33_18.

Ahearn CP, Gallo MC, Murphy TF. Insights on persistent airway infection by non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Pathog Dis. 2017 Jun 1;75(4):ftx042. doi:10.1093/femspd/ftx042.

Albini E, Belluco G, Berton M, Schioppacassi G, Ungheri D. In vitro antibacterial activity of thiamphenicol glycinate acetylcysteinate against respiratory pathogens. Arzneimittelforschung. 1999 Jun;49(6):533-7. doi:10.1055/s-0031-1300456.

Aldini G, Altomare A, Baron G, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018 Jul;52(7):751-762. doi:10.1080/10715762.2018.1468564.

Aslam S, Darouiche RO. Role of antibiofilm-antimicrobial agents in controlling device-related infections. Int J Artif Organs. 2011 Sep;34(9):752-8. doi:10.5301/ijao.5000024.

Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev. 2010 Jun;19(116):127-33. doi:10.1183/09059180.00003510.

Bear CE. 50 years ago in the Journal of Pediatrics: the effect of N-acetylcysteine on the viscosity of tracheobronchial secretions in cystic fibrosis of the pancreas. J Pediatr. 2013 Jan;162(1):85. doi:10.1016/j.jpeds.2012.08.006.

Blasi F, Page C, Rossolini GM, et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 2016 Aug;117:190-7. doi:10.1016/j.rmed.2016.06.015.

Calzetta L, Matera MG, Rogliani P, Cazzola M. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018 Aug;12(8):693-708. doi:10.1080/17476348.2018.1495562.

Cantu-Gonzalez G. 50 years ago in The Journal of Pediatrics: The use of N-acetylcysteine in the treatment of cystic fibrosis. J Pediatr. 2014 Oct;165(4):721. doi:10.1016/j.jpeds.2014.04.028.

Cataldi M, Sblendorio V, Leo A, Piazza O. Biofilm-dependent airway infections: a role for ambroxol? Pulm Pharmacol Ther. 2014 Aug;28(2):98-108. doi:10.1016/j.pupt.2013.11.002.

Cazan D, Klimek L, Sperl A, Plomer M, Kölsch S. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin Drug Saf. 2018 Dec;17(12):1211-1224. doi:10.1080/14740338.2018.1533954.

Chertoff J. N-Acetylcysteine's Role in Sepsis and Potential Benefit in Patients With Microcirculatory Derangements. J Intensive Care Med. 2018 Feb;33(2):87-96. doi:10.1177/0885066617696850.

Chughlay MF, Kramer N, Spearman CW, Werfalli M, Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. Br J Clin Pharmacol. 2016 Jun;81(6):1021-9. doi:10.1111/bcp.12880.

Ciacci N, Boncompagni S, Valzano F, et al. In Vitro Synergism of Colistin and N-acetylcysteine against Stenotrophomonas maltophilia. Antibiotics (Basel). 2019 Jul 25;8(3):101. doi:10.3390/antibiotics8030101.

del Prado G, Ruiz V, Naves P, Rodríguez-Cerrato V, Soriano F, del Carmen Ponte M. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-l-cysteine, amoxicillin, erythromycin, and levofloxacin. Diagn Microbiol Infect Dis. 2010 Aug;67(4):311-8. doi:10.1016/j.diagmicrobio.2010.03.016.

Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2942-8.

Domenech M, García E. N-Acetyl-l-Cysteine and Cysteamine as New Strategies against Mixed Biofilms of Nonencapsulated Streptococcus pneumoniae and Nontypeable Haemophilus influenzae. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01992-16. doi:10.1128/AAC.01992-16.

El-Baky RMA, El Ela DMMA, Gad GFM. N-acetylcysteine inhibits and eradicates Candida albicans biofilms. Am J Infect Di. Microbiol. 2014;2(5):122-130. doi:10.12691/ajidm-2-5-5.

El-Feky MA, El-Rehewy MS, Hassan MA, Abolella HA, Abd El-Baky RM, Gad GF. Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces. Pol J Microbiol. 2009;58(3):261-7.

Eroshenko D, Polyudova T, Korobov V. N-acetylcysteine inhibits growth, adhesion and biofilm formation of Gram-positive skin pathogens. Microb Pathog. 2017 Apr;105:145-152. doi:10.1016/j.micpath.2017.02.030.

Ershad M, Vearrier DN. N Acetylcysteine. Treasure Island (FL): StatPearls Publishing; 2020.

Fowdar K, Chen H, He Z, et al. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review. Heart Lung. 2017 Mar-Apr;46(2):120-128. doi:10.1016/j.hrtlng.2016.12.004.

Hamed S, Emara M, Shawky RM, El-Domany RA, Youssef T. Silver nanoparticles: Antimicrobial activity, cytotoxicity, and synergism with N-acetyl cysteine. J Basic Microbiol. 2017 Aug;57(8):659-668. doi:10.1002/jobm.201700087.

Jun Y, Youn CK, Jo ER, Cho SI. In vitro inhibitory activity of N-acetylcysteine on tympanostomy tube biofilms from methicillin-resistant Staphylococcus aureus and quinolone-resistant Pseudomonas aeruginosa. Int J Pediatr Otorhinolaryngol. 2019 Nov;126:109622. doi:10.1016/j.ijporl.2019.109622.

Kundukad B, Schussman M, Yang K, Seviour T, Yang L, Rice SA, Kjelleberg S, Doyle PS. Mechanistic action of weak acid drugs on biofilms. Sci Rep. 2017 Jul 6;7(1):4783. doi:10.1038/s41598-017-05178-3.

Kyd JM, McGrath J, Krishnamurthy A. Mechanisms of bacterial resistance to antibiotics in infections of COPD patients. Curr Drug Targets. 2011 Apr;12(4):521-30. doi:10.2174/138945011794751519.

Landini G, Di Maggio T, Sergio F, Docquier JD, Rossolini GM, Pallecchi L. Effect of High N-Acetylcysteine Concentrations on Antibiotic Activity against a Large Collection of Respiratory Pathogens. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7513-7517. doi:10.1128/AAC.01334-16.

Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front Cell Infect Microbiol. 2017 Mar 13;7:55. doi:10.3389/fcimb.2017.00055.

Leite B, Gomes F, Teixeira P, Souza C, Pizzolitto E, Oliveira R. Combined effect of linezolid and N-acetylcysteine against Staphylococcus epidermidis biofilms. Enferm Infecc Microbiol Clin. 2013 Dec;31(10):655-9. doi:10.1016/j.eimc.2012.11.011.

Minarini A, Ferrari S, Galletti M, et al. N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):279-292. doi:10.1080/17425255.2017.1251580.

Mohsen A, Gomaa A, Mohamed F, et al. Antibacterial, anti-biofilm activity of some non-steroidal anti-inflammatory drugs and N-acetyl cysteine against some biofilm producing uropathogens. Am J Epidemiol Infect Dis. 2015;3:1-9. doi:10.12691/ajeid-3-1-1.

Moon JH, Jang EY, Shim KS, Lee JY. In vitro effects of N-acetyl cysteine alone and in combination with antibiotics on Prevotella intermedia. J Microbiol. 2015 May;53(5):321-9. doi:10.1007/s12275-015-4500-2.

Moon JH, Choi YS, Lee HW, Heo JS, Chang SW, Lee JY. Antibacterial effects of N-acetylcysteine against endodontic pathogens. J Microbiol. 2016 Apr;54(4):322-9. doi:10.1007/s12275-016-5534-9.

Olofsson AC, Hermansson M, Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ Microbiol. 2003 Aug;69(8):4814-22. doi:10.1128/aem.69.8.4814-4822.2003.

Onger ME, Gocer H, Emir D, Kaplan S. N-acetylcysteine eradicates Pseudomonas aeruginosa biofilms in bone cement. Scanning. 2016 Nov;38(6):766-770. doi:10.1002/sca.21326.

Palaniswamy U, Lakkam SR, Arya S, Aravelli S. Effectiveness of N-acetyl cysteine, 2% chlorhexidine, and their combination as intracanal medicaments on Enterococcus faecalis biofilm. J Conserv Dent. 2016 Jan-Feb;19(1):17-20. doi:10.4103/0972-0707.173186.

Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. J Clin Microbiol. 1977 Jan;5(1):58-61.

Pei Y, Liu H, Yang Y, et al. Biological Activities and Potential Oral Applications of N-Acetylcysteine: Progress and Prospects. Oxid Med Cell Longev. 2018 Apr 22;2018:2835787. doi:10.1155/2018/2835787.

Pérez-Giraldo C, Rodríguez-Benito A, Morán FJ, Hurtado C, Blanco MT, Gómez-García AC. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother. 1997 May;39(5):643-6. doi:10.1093/jac/39.5.643.

Pollini S, Boncompagni S, Di Maggio T, et al. In vitro synergism of colistin in combination with N-acetylcysteine against Acinetobacter baumannii grown in planktonic phase and in biofilms. J Antimicrob Chemother. 2018 Sep 1;73(9):2388-2395. doi:10.1093/jac/dky185.

Pollini S, Di Pilato V, Landini G, et al. In vitro activity of N-acetylcysteine against Stenotrophomonas maltophilia and Burkholderia cepacia complex grown in planktonic phase and biofilm. PLoS One. 2018 Oct 1;13(10):e0203941. doi:10.1371/journal.pone.0203941.

Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019 May 20;5(5):CD001287. doi:10.1002/14651858.CD001287.pub6.

Ramachandran A, Jaeschke H. Acetaminophen Toxicity: Novel Insights Into Mechanisms and Future Perspectives. Gene Expr. 2018 Mar 21;18(1):19-30. doi:10.3727/105221617X15084371374138.

Rasmussen K, Nikrad J, Reilly C, Li Y, Jones RS. N-Acetyl-l-cysteine effects on multi-species oral biofilm formation and bacterial ecology. Lett Appl Microbiol. 2016 Jan;62(1):30-8. doi:10.1111/lam.12513.

Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Updat. 2016 Sep;28:82-90. doi:10.1016/j.drup.2016.07.003.

Riise GC, Larsson S, Larsson P, Jeansson S, Andersson BA. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J. 1994 Jan;7(1):94-101. doi:10.1183/09031936.94.07010094.

Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration. 2000;67(5):552-8. doi:10.1159/000067473.

Šalamon Š, Kramar B, Marolt TP, Poljšak B, Milisav I. Medical and Dietary Uses of N-Acetylcysteine. Antioxidants (Basel). 2019 Apr 28;8(5):111. doi:10.3390/antiox8050111.

Sanguinetti CM. N-acetylcysteine in COPD: why, how, and when? Multidiscip Respir Med. 2016 Feb 3;11:8. doi:10.1186/s40248-016-0039-2.

Snell G, Reed A, Stern M, Hadjiliadis D. The evolution of lung transplantation for cystic fibrosis: A 2017 update. J Cyst Fibros. 2017 Sep;16(5):553-564. doi:10.1016/j.jcf.2017.06.008.

Trifonova A, Strateva T. Stenotrophomonas maltophilia - a low-grade pathogen with numerous virulence factors. Infect Dis (Lond). 2019 Mar;51(3):168-178. doi:10.1080/23744235.2018.1531145.

Vardakas KZ, Voulgaris GL, Samonis G, Falagas ME. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018 Jan;51(1):1-9. doi:10.1016/j.ijantimicag.2017.05.016.

Young M, Ozcan A, Lee B, et al. N-acetyl Cysteine Coated Gallium Particles Demonstrate High Potency against Pseudomonas aeruginosa PAO1. Pathogens. 2019 Aug 1;8(3):120. doi:10.3390/pathogens8030120.

Zhan SH, French L. Sequence similarity searches for morphine biosynthesis enzymes in bacteria yield putative targets for understanding associations between infection and opiate administration. J Med Microbiol. 2019 Jun;68(6):952-956. doi:10.1099/jmm.0.001001.

Zhao T, Liu Y. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol. 2010 May 12;10:140. doi:10.1186/1471-2180-10-140.

Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol. 1999;43(2):107-13. doi:10.1111/j.1348-0421.1999.tb02381.x.

Downloads

Published

2021-09-10

How to Cite

Abaturov А., & Rusakova, O. (2021). Antibiofilm effects of mucolytic drugs. CHILD`S HEALTH, 15(6), 482–488. https://doi.org/10.22141/2224-0551.15.6.2020.215536

Issue

Section

Theoretical Medicine